Savara Inc (SVRA) Stock Price, Quote & News

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 512 614 1848

Website: www.savarapharma.com

Address:

1717 Langhorne Newtown Road, Suite 300, Langhorne, United States

justiceforb_85 Sep. 30 at 1:27 AM

$SVRA would be a good buyout for $INSM.

0 · Reply

Spacemonkey1 Sep. 29 at 1:27 PM

$SVRA more good news for FDA, though hard to gauge what’s going on at the FDA currently, as they are not trustworthy or reliable at this point,

0 · Reply

G101SPM Sep. 29 at 9:44 AM

$SVRA $3.52 bid. HOLDING LONG POSITION BRIEF: Savara presents new data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 Poster Summary: DLco% (a measure of pulmonary gas transfer) was chosen as the primary endpoint in the IMPALA-2 Phase 3 clinical trial because it is a standardized measure of pulmonary gas transfer widely used in clinical practice Previous research has shown that changes in DLco% correlate with changes in aPAP disease severity (i.e., surfactant accumulation/burden) and may predict the need for whole-lung lavage Post-hoc correlation analyses of IMPALA-2 data were conducted to evaluate the relationship between DLco% and measures of HRQoL, patient functionality, and surfactant burden in patients with aPAP Significant negative correlations were observed between DLco% and measures of respiratory HRQoL (SGRQ Total and Activity scores; higher scores indicate worse quality of life), as well as DLco% and surfactant accumulation (ground-glass opacity scores; lower scores indicate less surfactant) at Week 24. Significant positive correlations were observed between DLco% and patient functionality (exercise capacity expressed as peak METs; higher scores indicate improved exercise capacity) at Weeks 24 and 48 Results further support the clinical relevance of changes in DLco% in aPAP; changes in DLco% are associated with changes in clinical outcomes and the extent of pulmonary pathology, making it a clinically meaningful measure in this rare lung disease

0 · Reply

FreeBeerTomorrow Sep. 29 at 7:58 AM

$SVRA Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

0 · Reply

LegendaryCharts Sep. 28 at 4:15 PM

$PAVS Breaking out huge, could go crazy tomorrow, big watch in to premarket! Low float mania $ADTX Patent value is amazing on this $IXHL round 2 incoming $SVRA phase 3 news last month

0 · Reply

Social_Idiot Sep. 25 at 2:30 PM

$SVRA Respira Therapeutics being acquired, announced today.

0 · Reply

Richterscale Sep. 24 at 5:15 PM

$SVRA Anyone think this can cross $4 in the near term?

3 · Reply

Spacemonkey1 Sep. 23 at 9:43 PM

$SVRA hopefully someday, long investors are rewarded for their EXTREME patience with this company

0 · Reply

highnihilism Sep. 22 at 12:51 PM

IWM: Russell 2000 → $CMP Compass Minerals $KAR Openlane $WTTR Select Water Solutions $SVRA Savara $JELD Jeld-Wen Holding

0 · Reply

JarvisFlow Sep. 18 at 9:30 PM

Oppenheimer updates rating for Savara ( $SVRA ) to Outperform, target set at 15 → 5.

0 · Reply

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 2, 2025, 4:05 PM EDT - 2 days ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Sep 29, 2025, 2:00 AM EDT - 5 days ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 21, 2025, 7:14 AM EDT - 13 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Sep 15, 2025, 3:50 PM EDT - 19 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Sep 2, 2025, 9:00 AM EDT - 4 weeks ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Aug 26, 2025, 4:05 PM EDT - 5 weeks ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Aug 20, 2025, 5:15 PM EDT - 6 weeks ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 18, 2025, 8:05 AM EDT - 6 weeks ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 13, 2025, 8:05 AM EDT - 7 weeks ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Jul 18, 2025, 4:05 PM EDT - 2 months ago

Savara Announces New Employment Inducement Grant

May 28, 2025, 6:00 AM EDT - 4 months ago

Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 27, 2025, 3:40 PM EDT - 4 months ago

Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

May 27, 2025, 11:42 AM EDT - 4 months ago

BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

May 27, 2025, 8:05 AM EDT - 4 months ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

May 22, 2025, 9:05 AM EDT - 4 months ago

Savara Announces Participation in Jefferies Global Healthcare Conference

May 18, 2025, 2:30 PM EDT - 4 months ago

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

May 13, 2025, 4:05 PM EDT - 5 months ago

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

May 1, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Apr 21, 2025, 11:16 AM EDT - 5 months ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 7, 2025, 4:05 PM EDT - 6 months ago

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Mar 27, 2025, 7:05 AM EDT - 6 months ago

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 26, 2025, 4:45 PM EDT - 6 months ago

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

HTGC

Mar 26, 2025, 4:05 PM EDT - 6 months ago

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 17, 2025, 8:05 AM EDT - 7 months ago

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Mar 6, 2025, 8:05 AM EST - 7 months ago

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Mar 3, 2025, 4:15 PM EST - 7 months ago

Savara Announces Participation in the Leerink Global Healthcare Conference

Jan 30, 2025, 8:39 AM EST - 8 months ago

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Jan 29, 2025, 4:05 PM EST - 8 months ago

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Dec 18, 2024, 4:05 PM EST - 10 months ago

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Dec 17, 2024, 4:05 PM EST - 10 months ago

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 22, 2024, 8:05 AM EST - 11 months ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Nov 13, 2024, 8:05 AM EST - 11 months ago

Savara Announces Participation in Upcoming Healthcare Conferences

Nov 12, 2024, 8:05 AM EST - 11 months ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:05 PM EST - 11 months ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 22, 2024, 8:05 AM EDT - 1 year ago

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

justiceforb_85 Sep. 30 at 1:27 AM

$SVRA would be a good buyout for $INSM.

0 · Reply

Spacemonkey1 Sep. 29 at 1:27 PM

$SVRA more good news for FDA, though hard to gauge what’s going on at the FDA currently, as they are not trustworthy or reliable at this point,

0 · Reply

G101SPM Sep. 29 at 9:44 AM

0 · Reply

FreeBeerTomorrow Sep. 29 at 7:58 AM

0 · Reply

LegendaryCharts Sep. 28 at 4:15 PM

$PAVS Breaking out huge, could go crazy tomorrow, big watch in to premarket! Low float mania $ADTX Patent value is amazing on this $IXHL round 2 incoming $SVRA phase 3 news last month

0 · Reply

Social_Idiot Sep. 25 at 2:30 PM

$SVRA Respira Therapeutics being acquired, announced today.

0 · Reply

Richterscale Sep. 24 at 5:15 PM

$SVRA Anyone think this can cross $4 in the near term?

3 · Reply

Spacemonkey1 Sep. 23 at 9:43 PM

$SVRA hopefully someday, long investors are rewarded for their EXTREME patience with this company

0 · Reply

highnihilism Sep. 22 at 12:51 PM

IWM: Russell 2000 → $CMP Compass Minerals $KAR Openlane $WTTR Select Water Solutions $SVRA Savara $JELD Jeld-Wen Holding

0 · Reply

JarvisFlow Sep. 18 at 9:30 PM

Oppenheimer updates rating for Savara ( $SVRA ) to Outperform, target set at 15 → 5.

0 · Reply

highnihilism Sep. 17 at 9:43 AM

IWM: Russell 2000 → $CMP Compass Minerals $KAR Openlane $WTTR Select Water Solutions $SVRA Savara $JELD Jeld-Wen Holding

0 · Reply

STOCKALERTIST Sep. 11 at 1:42 PM

$NVAX sharply up and $SVRA is squeezing

0 · Reply

STOCKALERTIST Sep. 11 at 1:40 PM

$SVRA expect this to cross $3.95 today ad over $4.00 the the major squeeze will start. stock up!!!!

1 · Reply

STOCKALERTIST Sep. 11 at 1:34 PM

$SVRA could squeeze!!

0 · Reply

JarvisFlow Sep. 9 at 1:00 PM

Guggenheim has updated their rating for Savara ( $SVRA ) to Buy with a price target of 11.

0 · Reply

art62 Sep. 8 at 7:07 PM

$SVRA Prior post credit to A. Tsai Jefferies---> eaning 12-15 dollars

1 · Reply

art62 Sep. 8 at 7:02 PM

$SVRA ".... (1) The completion of CMC work by early Q4 with drug supplier Fujifilm (+5-10% stock move) should trigger add'l catalysts, such as (2) a BLA acceptance in Q1:26 (+5-15% move), (3) AdCom in mid-2026 (perhaps +15-35%), and (4) PDUFA as early as Aug 2026..Mgmt's latest market research confirms the diagnosed US population could actually be 50% larger, prompting us to raise our peak sales estimate to $500M (up from prior $400M), which could still be conservative. Net-net, $500M sales x high 4-5x multiple (biosimilar competition is unlikely) = $2.0-2.5B valuation (up from $800M+ cap)."

0 · Reply

IN0V8 Sep. 8 at 3:01 PM

$SVRA Opportunity to watch Jefferies raises target price to $10.5 from $8.5

0 · Reply

JarvisFlow Sep. 8 at 12:30 PM

Oppenheimer updates rating for Savara ( $SVRA ) to Outperform, target set at 6 → 8.

0 · Reply

TeeMan123 Sep. 8 at 12:34 AM

$SVRA Jefferies increases price target to $10.50 .. increasing peak sales expectations to $500MM

0 · Reply

STOCKALERTIST Sep. 5 at 7:25 PM

$SOUN and $SVRA is squeezing!!!

0 · Reply

STOCKALERTIST Sep. 5 at 4:04 PM

$NVAX is curling and $SVRA is squeezing

0 · Reply

Market Cap	603.20M
Revenue (ttm)	0.00
Net Income (ttm)	-95.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.25

Volume	724,200
Avg Vol	1,413,134
Day's Range	N/A - N/A
Shares Out	172.84M
Stochastic %K	44%
Beta	0.46
Analysts	Strong Sell
Price Target	$9.79